Table 1.
Clinical characteristics of COVID‐19 patients with different duration of viral shedding
| Total (n = 66) | DVS ≤ 11 d (n = 35) | DVS>11 d (n = 31) | P | |
|---|---|---|---|---|
| Demographics and clinical characteristics | ||||
| Age, y | 47.5 (36‐63.5) | 46 (31‐60) | 59 (39‐67) | .042 |
| Female | 26 (39.39%) | 10 (28.6%) | 16 (51.6%) | .056 |
| Smoker | 4 (6.1%) | 2 (5.7%) | 2 (6.5%) | .900 |
| Comorbidity | ||||
| Hypertension | 19 (28.79) | 7 (20%) | 12 (38.7%) | .094 |
| Diabetes | 6 (9.09%) | 3 (8.6%) | 3 (9.7%) | .876 |
| Cerebrovascular diseases | 8 (12.12%) | 4 (11.4%) | 4 (12.9%) | .855 |
| Chronic obstructive lung disease | 2 (3.03%) | 0 (0%) | 2 (6.5%) | .217 |
| Chronic kidney disease | 1 (1.51%) | 1 (2.9%) | 0 (0%) | 1.000 |
| Chronic liver disease | 6 (9.09%) | 2 (5.7%) | 4 (12.9%) | .559 |
| Carcinoma | 3 (4.55%) | 1 (2.9%) | 2 (6.5%) | .914 |
| T max (temperature>38.5°C) | 28 (42.42%) | 9 (25.7%) | 19 (61.3%) | .004 |
| Disease severity | .004 | |||
| General | 46 (69.69%) | 30 (85.7%) | 16 (51.6%) | |
| Severe | 11 (16.67%) | 4 (11.4%) | 7 (22.6%) | |
| Critical | 9 (13.63%) | 1 (2.9%) | 8 (25.8%) | |
| Time from onset to hospitalization, d | 4 (3‐5) | 4 (2‐5) | 5 (4‐6) | .008 |
| Laboratory findings | ||||
| White blood cell count, ×109/L | 4.11 (3.445‐5.66) | 3.95 (3.455.42) | 4.26 (3.43‐6.49) | .379 |
| Lymphocyte count, ×109/L | 1.1 (0.76‐1.5) | 1.2 (0.77‐1.49) | 0.99 (0.75‐1.53) | .181 |
| Hemoglobin, g/L | 137.5 (124.75‐144.25) | 133 (123‐142) | 141 (133‐152) | .041 |
| Anemia | 7 (10.61%) | 4 (11.4%) | 3 (9.7%) | .817 |
| Platelet count, ×109/L | 178 (148.75‐219.5) | 190 (148‐257) | 168 (151‐209) | .107 |
| Prothrombin time, s | 12.6 (11.9‐13.1) | 12.4 (11.9‐13) | 12.7 (12‐13.2) | .541 |
| ALT, U/L | 28 (21‐46.25) | 28 (19‐46) | 28 (23‐52) | .252 |
| AST, U/L | 29.5 (20.75‐42) | 29 (19‐41) | 30 (23‐50) | .289 |
| Albumin, g/L | 37.15 (33.675‐39.8) | 37.4 (34‐39.3) | 36.7 (32‐41) | .959 |
| Creatine kinase, U/L | 70 (46‐116) | 60.5 (45.75‐98.75) | 87 (46‐142) | .219 |
| Creatinine, μmol/L | 63.5 (54.5‐77.25) | 61 (53‐74) | 66 (58‐78) | .452 |
| C‐reactive protein, mg/L | 13.6 (2.6‐28.65) | 14 (2.3‐26.3) | 13.5 (3.2‐51.1) | .396 |
| Procalcitonin, ng/mL | 0.11 (0.1‐0.14) | 0.12 (0.1‐0.14) | 0.11 (0.1‐0.14) | .916 |
| Treatments | ||||
| Antibiotics | 7 (10.61%) | 1 (2.9%) | 6 (19.4%) | .076 |
| Antiviral treatment | 40 (60.61%) | 23 (65.7%) | 17 (54.8%) | .367 |
| TCM treatment | 58 (87.88%) | 30 (88.2%) | 28 (93.3%) | .788 |
| Corticosteroids | 17 (25.76%) | 4 (11.4%) | 13 (41.9%) | .005 |
| Oxygen support therapy | 62 (93.94%) | 33 (94.3%) | 29 (93.5%) | .900 |
| Noninvasive mechanical ventilation | 3 (4.55%) | 0 (0%) | 3 (9.7%) | .196 |
| Invasive mechanical ventilation | 3 (4.55%) | 0 (0%) | 3 (9.7%) | .196 |
| ECMO | 2(3.03%) | 0 (0%) | 2 (6.5%) | .420 |
| Outcomes | ||||
| ARDS | 7 (10.61) | 2 (5.7%) | 5 (16.1%) | .332 |
| Septic shock | 4 (6.06%) | 0 (0%) | 4 (12.9%) | .094 |
| Acute cardiac injury | 4 (6.06%) | 0 (0%) | 4 (12.9%) | .094 |
| Acute kidney injury | 3 (4.55%) | 0 (0%) | 3 (9.7%) | .196 |
| Acute liver injury | 23 (34.85%) | 10 (28.6%) | 13 (41.9%) | .255 |
| Secondary infection | 7 (10.61%) | 1 (2.9%) | 6 (19.4%) | .076 |
| ICU admission | 5 (7.57) | 0 (0%) | 5 (16.1%) | .045 |
| Death | 2 (3.03%) | 0 (0%) | 2 (6.5%) | .420 |
| Hospital length of stay, d | 15 (10.25‐18) | 13 (10‐16) | 17 (12.5‐18) | .040 |
Abbreviations: ALT, alanine aminotransferase; ARDS, adult respiratory distress syndrome; AST, aspartate transaminase; COVID‐19, coronavirus disease 2019; DVS, duration of viral shedding; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.